Trends in male breast cancer in Spain, 1999–2023: a nationwide analysis of incidence and mortality
Clinical and Translational Oncology · 30.03.2026 · 28 (9) · 3872-3879
DOI: 10.1007/s12094-026-04328-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 30.03.2026. Verfasst von Lucía Cayuela und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital Severo Ochoa, Leganés, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Male. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Male breast cancer (MBC) is rare and increasing globally, with limited data on trends in Spain. The study examines MBC trends, incidence, and mortality over a 25 year period (1999-2023) to guide public health strategies. METHODS: An ecological trend study was conducted using national mortality data from the Spanish National Statistics Institute and modeled incidence estimates from the Global Burden of Disease Study 2023. Age-standardized incidence and mortality rates (ASIR and ASMR) per 100,000 men were calculated using the European Standard Population 2013. Joinpoint regression identified temporal inflection points. Age-Period-Cohort (APC) modeling quantified age, period, and cohort effects for men aged 30-84 years. RESULTS: The study recorded 7594 MBC cases and 1,931 deaths. ASMR declined from 0.65 to 0.39 per 100,000 (AAPC - 1.8%), with significant declines from 1999-2006 (APC - 5.1%) and 2013-2023 (APC - 3.6%). ASIR remained largely stable (AAPC 0.1%), increasing slightly from 1999-2006 (APC + 1.7%) and declining thereafter (APC - 0.5%). The Mortality-to-Incidence Ratio decreased from 0.41 to 0.26. APC analysis demonstrated significant net declines in mortality (- 1.33%/year) and incidence (- 0.83%/year), primarily driven by period effects and lower risk among later birth cohorts. Mortality reductions were most pronounced among men aged 55-64 years. CONCLUSION: MBC mortality in Spain has declined steadily, reflecting improvements in clinical management, while stable incidence indicates minimal change in disease occurrence. Continued focus on early detection, male-specific awareness, and adherence to guideline-based therapy is essential to further reduce the MBC burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital Severo Ochoa, Leganés, Spain.
- Palliative Care Working Group of the Spanish Society of Internal Medicine (SEMI), Madrid, Spain.
- Navarrabiomed-HUN-UPNA, Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de La Saluds (RICAPPS), Pamplona, Spain. julian.librero@gmail.com.
- Independent Researcher, Seville, Spain.
Zitieren
APA
Cayuela, L., Achaval, V., Flox-Benítez, G., Librero, J., & Cayuela, A. (2026). Trends in male breast cancer in Spain, 1999–2023: a nationwide analysis of incidence and mortality. Clinical and Translational Oncology, 28(9), 3872-3879. https://doi.org/10.1007/s12094-026-04328-2
Vancouver
Cayuela L, Achaval V, Flox-Benítez G, Librero J, Cayuela A. Trends in male breast cancer in Spain, 1999–2023: a nationwide analysis of incidence and mortality. Clinical and Translational Oncology. 2026;28(9):3872-3879. doi:10.1007/s12094-026-04328-2
BibTeX
@article{Cayuela2026,
author = {Cayuela, Lucía and Achaval, Victoria and Flox-Benítez, Gema and Librero, Julián and Cayuela, Aurelio},
title = {Trends in male breast cancer in Spain, 1999–2023: a nationwide analysis of incidence and mortality},
journal = {Clinical and Translational Oncology},
year = {2026},
volume = {28},
number = {9},
pages = {3872--3879},
doi = {10.1007/s12094-026-04328-2}
}
EUVIMED